hyperinsulinemic euglycemic clamp-Turku University Hospital

The hyperinsulinemic euglycemic clamp-Turku University Hospital refers to a specific clinical trial intervention protocol used to assess insulin sensitivity and metabolic function. This procedure involves the simultaneous intravenous administration of a fast-acting insulin analogue (insulin aspart, brand name NovoRapid) and a 20% glucose solution. The insulin is infused at a constant rate to elevate plasma insulin levels, while the glucose infusion rate is dynamically adjusted to maintain blood glucose at a target euglycemic level (typically 5.0 mmol/L). Developed and utilized by Turku University Hospital, this protocol is often combined with advanced imaging techniques like PET/CT using [18F]FDG and H2[15O]O to quantify tissue-specific glucose uptake and blood flow. It is primarily employed in Phase 4 clinical research to study metabolic alterations in conditions such as obesity.

Brand names

NovoRapid

Other names

Hyperinsulinemic euglycemic clampHECinsulin aspart + glucose